Symphony Automated 12 Channel Solid Phase Bio-Organic Synthesizer

描述(由申请人提供)：波士顿生物医学研究所(BBRI)的研究人员追求一系列不同的研究兴趣，其统一目标是阐明人类疾病中出错的正常细胞和分子机制。在全研究所范围内，癌症生物学、再生生物学、心血管生物学和整合蛋白质生物学的程序性研究的推动力是为了使生物医学和医疗疗法取得新的进展。为了提高生物医学研究项目的质量和范围，BBRI的研究人员正在申请资金购买由Protein Technologies，Inc.制造的SYMPHONY自动12通道固相生物有机合成器。该仪器是一种最先进的多肽合成器，具有同时合成多达12个多肽的能力。每次合成都可以进行定制设计，以指定唯一的偶合时间、重复偶合等，以提高最终产品的质量。该仪器的另一个特点是它可以在5微米到3毫米的范围内合成多肽。交响乐器将被安置在监督私人投资者的实验室里，私人投资者目前是研究所多肽核心的负责人。他 他的技术助理将负责仪器的日常操作和维护；将在多肽设计和合成战略方面提供持续的咨询和协助；并为其他潜在用户提供适当的培训。额外的一般监督和使用审查将由一带一路研究委员会(COR)提供，该委员会是一个内部科学咨询委员会，由代表一带一路全方位研究兴趣和专业知识的教职员工组成。BRI一贯支持多肽合成，并致力于为支持新仪器提供空间、服务合同和运营成本。11个一带一路研究项目将在收购交响乐器后实现立即和持续的进展加速。其中包括7个R01级、资助的高级和初级调查人员的研究计划，他们将是主要用户，以及4个次要用户，包括3名新调查人员的新兴研究计划。该仪器还将加强总部位于BBRI的Wellstone合作性肌营养不良症研究中心的研究。

DESCRIPTION (provided by applicant): Investigators at Boston Biomedical Research Institute (BBRI) pursue a diverse range of research interests that have the unifying goal of elucidating normal cellular and molecular mechanisms that go awry in human disease. Institute-wide, programmatic research thrusts in Cancer Biology, Regenerative Biology, Cardiovascular Biology, and Integrative Protein Biology are motivated by the intent to enable new advances in biomedicine and medical therapies. To enhance the quality and scope of their biomedical research programs, investigators at BBRI are applying for funds to purchase a Symphony Automated 12-Channel Solid Phase Bio-Organic Synthesizer manufactured by Protein Technologies, Inc. This instrument is a state-of-the-art peptide synthesizer that has the capability to synthesize up to 12 peptides simultaneously. Each synthesis can be custom designed to allow assigning unique coupling times, repeat couplings, etc, to enhance the quality of the final products. Another feature of the instrument is that it allows peptides to be synthesized at scales ranging from 5 uM to 3 mM. The Symphony instrument will be housed within the laboratory of the overseeing P.I. who currently directs the Institute's Peptide Core. He and his technical associate would be responsible for the day-to-day operation and maintenance of the instrument; would provide ongoing consultation and assistance in peptide design and synthesis strategies; and provide proper training to other potential users. Additional general oversight and usage review will be provided by BBRI's Committee on Research (COR), which is an internal scientific advisory committee composed of faculty who represent the full range of research interests and expertise at BBRI. BBRI has consistently supported peptide synthesis and is committed to providing space, service contracts, and operational costs for support of the new instrument. Eleven BBRI research programs will realize an immediate and sustained acceleration of progress upon acquisition of the Symphony Instrument. These include the research programs of 7 R01-level, funded senior and junior investigators, who will be major users, and 4 minor users, including the emerging research programs of 3 new investigators. The instrument will also enhance research in a Wellstone Cooperative Muscular Dystrophy Research Center headquartered at BBRI.